Amylyx Pharmaceuticals, Inc. 8-K

What Happened
Amylyx Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2025 via a press release dated March 3, 2026. The company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The Form 8-K notes that the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.

Key Details

• Press release announcing quarter and fiscal year results dated March 3, 2026 (Exhibit 99.1).
• Results cover the quarter and fiscal year ended December 31, 2025 (Item 2.02).
• The Form 8-K was signed by James M. Frates, Chief Financial Officer, on March 3, 2026.
• The company furnished (but did not file) the release, limiting Section 18 liability and incorporation by reference.

Why It Matters
This Form 8-K signals that Amylyx has released its latest earnings and financial-condition information; investors should review the March 3, 2026 press release (Exhibit 99.1) for details on revenue, net income/loss, cash position, and guidance that could affect the stock. Note the legal disclosure that the release is furnished rather than filed, which affects how the information is treated in other SEC filings.